Original Research

Cost-effectiveness of the Collaborative Care to Preserve Performance in Cancer (COPE) trial tele-rehabilitation interventions for patients with advanced cancers

Colleen F. Longacre1 | John A. Nyman1 | Sue L. Visscher2 | Bijan J. Borah2 | Andrea L. Cheville3

1Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA
2Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA
3Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, USA

Correspondence
Andrea L. Cheville, Mayo Clinic 200 First Street SW, Rochester, MN 55905, USA.
Email: cheville.andrea@mayo.edu

Funding information
National Cancer Institute, Grant/Award Number: R01 CA163803

Abstract

Purpose: The purpose of this analysis was to determine the cost-effectiveness of a Collaborative Care Model (CCM)-based, centralized telecare approach to delivering rehabilitation services to late-stage cancer patients experiencing functional limitations.

Methods: Data for this analysis came from the Collaborative Care to Preserve Performance in Cancer (COPE) trial, a randomized control trial of 516 patients assigned to: (a) a control group (arm A), (b) tele-rehabilitation (arm B), and (c) tele-rehabilitation plus pharmacological pain management (arm C). Patient quality of life was measured using the EQ-5D-3L at baseline, 3-month, and 6-month follow-up. Direct intervention costs were measured from the experience of the trial. Participants’ hospitalization data were obtained from their medical records, and costs associated with these encounters were estimated from unit cost data and hospital-associated utilization information found in the literature. A secondary analysis of total utilization costs was conducted for the subset of COPE trial patients for whom comprehensive cost capture was possible.

Results: In the intervention-only model, tele-rehabilitation (arm B) was found to be the dominant strategy, with an incremental cost-effectiveness ratio (ICER) of $15,494/QALY. At the $100,000 willingness-to-pay threshold, this tele-rehabilitation was the cost-effective strategy in 95.4% of simulations. It was found to be cost saving compared to enhanced usual care once the downstream hospitalization costs were taken into account. In the total cost analysis, total inpatient hospitalization costs were significantly lower in both tele-rehabilitation (arm B) and tele-rehabilitation plus pain management (arm C) compared to control (arm A), (P = 0.048).

Conclusion: The delivery of a CCM-based, centralized tele-rehabilitation intervention to patients with advanced stage cancer is highly cost-effective. Clinicians and care teams working with this vulnerable population should consider incorporating such interventions into their patient care plans.

Keywords
cost effectiveness, healthcare utilization, hospitalization, physical function, telecare
"Health-care costs related to cancer increase at a rate that far exceeds inflation, leaving few patients unaffected. The consequences of this escalation include an almost threefold higher rate of personal bankruptcy among patients with cancer, with reports establishing "financial toxicity," that is, problems related to the cost of treatment, as a clear threat to patients’ survival. Spiraling drug costs have been highlighted as an important contributor. However, expenses rapidly mount from diverse sources including diagnostic testing, clinician visits, and symptom management, suggesting that an exclusive focus on any single charge category will fail to meaningfully improve the situation. Payment-based solutions, such as bundled care and episode-based reimbursement, have been slow to gain traction, and credible targets to ease patients’ financial strain remain elusive.

Given the mounting concern over cancer costs, surprisingly, limited attention has been directed to potentially remediable drivers of patients’ requirement for health-care services, namely pain and disablement. Associations between patients’ pain and their hospital and emergency department usage have been long recognized, particularly among cancer cohorts. However, linkages between patients’ functional status and their health-care consumption, though robust, have received less attention. Further, until recently, associations of health-care costs with adverse symptoms and loss of function were considered neither causal nor remediable. These assumptions have been challenged by reports of reduced hospital and emergency department service utilization among patients randomized to quality of life- and symptom-directed interventions that improve pain and/or function. The recently reported Collaborative Care to Preserve Performance in Cancer (COPE) was notable among these efforts as the first to validated among patients with cancer. Participants who were experiencing functional limitations to: (a) a control group (arm A), (b) tele-rehabilitation (arm B), and (c) tele-rehabilitation plus pharmacological pain management (arm C). Clinical outcomes of this trial have been reported elsewhere. All arms underwent automated home-based monitoring of physical functioning and pain via telephone and/or internet, with reporting of these data to their care teams. Participants in arms B and C received centralized tele-rehabilitation based on the collaborative care model (CCM) provided by a physical therapist (PT) physician team. The tele-rehabilitation intervention included a pedometer-based walking program and a resistive exercise program, both validated. Direction was provided remotely via telephone during one-to-one calls between participants and the study PTs. Arm C participants also received similarly delivered, nurse-coordinated pain management based on an iteration of the CCM previously validated among patients with cancer. Participants who did not complete their scheduled assessments, did not adhere to the recommended frequency of exercise sessions, or reported functional losses were contacted by a PT for further follow-up.

The COPE trial was conducted at three academic medical centers located in the upper Midwest, Southwest, and Southeast sections of the United States. All sites were part of a single health-care system and National Cancer Institute-designated comprehensive cancer center. COPE trial participants were seen for at least two visits in an outpatient medical oncology or hematology clinic at one of the sites.

Patient quality of life was measured using the EQ-5D-3L at baseline, and at 3- and 6-month follow-up. The EQ-5D-3L has robust support for validity in populations with advanced malignancies. Direct intervention costs were measured from the experience of the trial. Participants’ hospitalization data were obtained through abstracting the medical record, and costs associated with these encounters were estimated from unit cost data and hospital-associated utilization information found in the literature. A secondary analysis of total utilization costs was conducted for the subset of COPE trial patients living in Olmsted County, whose data were available from the Rochester Epidemiology Project (REP).

2.2 The decision-analysis model

A decision-analytic model was constructed using TreeAgePro software (2017) to assess the three intervention strategies examined in the COPE trial (Figure 1).
Participants were assumed to receive the full intervention of the arm to which they were assigned. Participants could experience health-care utilization in the form of hospitalizations. Each hospitalization was associated with a length of stay (in days).

### 2.3 Parameter estimates

Table 1 provides the full list of parameter estimates and distributions used in the model.

#### 2.3.1 Effectiveness

The incremental utility gain per arm was measured by the incremental change in EQ-5D-3L score per arm over the course of the trial. We assumed a linear increase in effectiveness between baseline and 6 months and that utility gains only lasted until
the conclusion of the trial. The incremental utility gain over the 6-month trial period was then converted into quality-adjusted life years (QALYs) for the cost-effectiveness analysis.

2.3.2  |  Costs

**Intervention costs**
Fixed intervention costs for participants in trial arm B included: (a) the cost of instructional DVDs and elastic resistance bands used by the “Rapid Easy Strength Training” resistive exercise program; and (b) the cost of pedometers associated with the “First Step Program”, an incremental pedometer-based walking program. Variable intervention costs for participants in trial arm B included time spent on the phone with a PT, the “fitness care manager” (FCM), who has specialized in cancer rehabilitation. The dates and lengths of these telephone calls were recorded, and the cost of the calls were calculated based on the salaries of the FCMs participating in the trial. In addition to the fixed and variable costs associated with arm B, the variable costs for arm C included the time spent on the phone with a nurse “pain care manager” (PCM), who reached out to those patients with high pain scores and provided treatment recommendations to the study participant’s oncologic, hematologic, or primary care team, who were responsible for prescribing all medications. The dates and lengths of telephone calls with patients were recorded, and these time costs were calculated, based on the salaries of the PCMs participating in the trial. Consultative meetings were held biweekly and the time spent in these meetings was not tracked by the patient; therefore, PCM time costs for meetings are considered fixed.

**Utilization costs**
We estimated health-care utilization costs in two ways: (a) by applying unit cost estimates from the literature to collected hospital utilization data and (b) collecting cost data from a subset of the patient population of the COPE trial tracked by the REP.

**Estimated hospitalization costs from the literature**
The COPE trial tracked utilization (participant hospitalizations and hospital lengths of stay), but did not track the total costs associated with these visits. As a result, hospitalization costs were estimated using unit costs from the literature. Because patients in the COPE trial with stage III-IV cancers are likely to be significantly different from the overall population of hospital patients surveyed in most cost studies, estimates of cancer treatment costs were not included. Instead, because we had participant length of stay, we used a measure of the hospital-adjusted expenses per inpatient day, estimated from the Kaiser Family Foundation in 2015. This figure provides an estimate of expenses incurred by the hospital to provide a day of inpatient care, but does not include the cost of specific services (procedures or treatments) provided to the patient.

**Estimated costs from the REP**
While complete utilization cost data were not available for all trial participants, these data were available from the REP for a subset of COPE trial participants who were living in Olmsted County, Minnesota. The REP is a medical records-linkage system that tracks virtually all health-care services provided to the residents of Olmsted County, Minnesota by Olmsted County-based providers. The population counts obtained by the REP Census match those obtained by the US Census, indicating that the population of the county is captured by the system. The REP tracks the vital and residential status of all Olmsted residents, and capture billing codes for all their health care. From the REP data, we estimated the total costs, cancer-related inpatient costs, cancer-related outpatient costs, cancer-related emergency department costs, and all-cause clinic costs. The REP reports standardized costs, which are created from an internally developed algorithm that applies Medicare reimbursement to professional services, multiplies the charges for hospital services by the appropriate Medicare cost report cost-to-charge ratios, and adjusts for inflation with the GDP implicit price deflator. This standardization process, however, renders these costs incomparable with the costs of the direct intervention because of the proprietary nature of the standardization algorithm. Therefore, we did not calculate cost-effectiveness measures from these data. Instead, we calculated Wilcoxon scores (rank sums) for these cost measures and determined whether these costs varied significantly across the three arms using the Kruskal-Wallis nonparametric analysis of variance test.

2.3.3  |  Cost-effectiveness measures

**Incremental cost-effectiveness ratio**
We used the ICER as a point estimate of the cost-effective treatment strategy.

**Probabilistic sensitivity analysis**
Where appropriate, we then ran a probabilistic sensitivity analysis (PSA) of 100 000 simulations using the means, assumed distribution and confidence intervals from the cost and effectiveness results to determine and construct the cost-effectiveness acceptability curve (CEAC) associated with the treatment strategies. The CEAC allows us to summarize which strategy is more likely to be cost-effective at various willingness-to-pay thresholds.

3  |  RESULTS

Table 2 compares the demographic and clinical characteristics of the patients in the COPE trial who were and were not captured in the REP data. Participants in the REP data were more likely than non-REP patients to receive chemotherapy as part...
of their cancer treatment; otherwise, the two cohorts did not differ significantly in their sociodemographic characteristics, clinical presentation, and outcomes reported at baseline.

The mean cost of the intervention per patient was $154.94 in arm B and $270.18 in arm C (Table 3). Staff time spent on calls with patients was the largest contributor to the intervention cost.
costs (65% in arm B and 48% in arm C), followed by the time spent in consultative meetings by the PCMs in arm C (32% of arm C costs). The mean QALY gain in arm B was 0.01 (3.65 days of the equivalent of perfect health) and in arm C was 0.0075 (2.74 such days), both compared to control arm A.

We present two types of results for each of our two cost-effectiveness analyses: (a) the expected (mean) costs and effectiveness (QALYs) and the ICER derived from these; and (b) the results of the PSA. We then provide results of the cost analysis of the REP data.

### 3.1 | Intervention-only

Our initial model looked only at the direct costs of the intervention. The mean incremental cost of tele-rehabilitation (arm B) over enhanced usual care (arm A) was $154.94 per patient, while the corresponding mean effectiveness gain was 0.01 QALYs, for an ICER of $15 494/QALY (Table 3). A strategy is considered dominated if it is both more costly and less effective than another strategy. Arm C was found to be more costly and less effective than arm B; therefore, tele-rehabilitation plus pain management (arm C) was dominated by tele-rehabilitation alone (arm B). At the $100 000 willingness-to-pay threshold, tele-rehabilitation (arm B) was found to be the cost-effective strategy in 95.4% of simulations, compared to enhanced usual care (arm A), which was the cost-effective strategy in only 4.6% of simulations. Because of the relatively low overall cost of the intervention, tele-rehabilitation became cost-effective at willingness-to-pay thresholds as low as $15 494, as shown in the cost-effectiveness acceptability curve (Figure 2).

| Arm Description | Mean cost | Mean effectiveness (QALY) gain | ICER |
|-----------------|-----------|--------------------------------|------|
| Intervention-only |           |                                |      |
| A Enhanced usual care | $0.00 | 0 | — |
| C Tele-rehabilitation plus pain management | $270.18 | 0.0075 | dominated |
| B Tele-rehabilitation | $154.94 | 0.01 | 15 494 |
| Intervention plus hospitalization |           |                                |      |
| A Enhanced usual care | $3423.13 | 0 | dominated |
| C Tele-rehabilitation plus pain management | $3077.54 | 0.0075 | dominated |
| B Tele-rehabilitation | $2018.54 | 0.01 | cost savings |

**TABLE 3** Incremental cost-effectiveness ratio (ICER) point estimates for the intervention-only and intervention plus hospitalization models
3.2 | Intervention plus hospitalization costs

Our second model incorporated the probabilities of hospitalizations and estimated lengths of stay, and associated costs estimated from the literature. The mean cost for tele-rehabilitation (arm B) was $1420 lower than for enhanced usual care (arm A) while the mean effectiveness gain remained at 0.01 QALYs (Table 3). Thus, the tele-rehabilitation intervention was found to be cost saving compared to enhanced usual care once the downstream hospitalization costs were taken into account. Tele-rehabilitation plus pain management (arm C) was again dominated by tele-rehabilitation (arm B), as arm C was again more costly and less effective.

3.3 | Full cost data for REP patients

Table 4 presents the results of the cost analysis conducted on the subset of COPE trial participants represented in the REP data. Among these participants, patients in the tele-rehabilitation arm (arm B) had mean total costs that were 13.6% lower than patients in the tele-rehabilitation plus pain management arm (arm C) and 25% lower than patients in the enhanced usual care arm (arm A), though neither of these results were statistically significant. However, total inpatient hospitalization costs differed significantly across the three trial arms ($P = .048$). Outpatient, emergency department, and clinic costs did not differ significantly across the three arms. Importantly, the REP-based ranking of costs matched our previous ranking of costs based on hospital length of stay.

4 | DISCUSSION

Care delivered to individuals with advanced stage cancers represents a large cost burden to the health-care system, in part due to patients’ adverse symptoms and loss of function. Tele-rehabilitation, based on the CCM model, is a low-cost, low-intensity intervention that was found in the COPE trial to improve patients’ quality of life, function, and pain. We conducted cost-effectiveness analyses comparing the COPE trial arms and found that the tele-rehabilitation intervention was cost-effective at a willingness-to-pay threshold of only $15 494/QALY (Figure 2), which is considerably below standard willingness-to-pay thresholds of $50 000 or $100 000 established in the medical and health economics literatures. Additionally, the tele-rehabilitation intervention became cost savings when downstream hospitalization costs were taken into account.

The COPE trial intervention is a patient-centric approach that meets requirements, identified by the National Academy of Medicine, to improve the experiences and outcomes of patients with cancer. As payment for cancer care evolves, oncology care providers will likely be incentivized to address patients’ functional losses through bundled reimbursement initiatives, not only to avoid costly downstream disablement, but also because functional autonomy is an unwavering patient priority. Insurance coverage of the telecare approach employed in COPE is, at present, limited by constraints on federal and commercial payers. However, the accelerating shift away from fee-for-service toward value-based reimbursement likely will allow for more flexible delivery approaches that do not confine payment to clinic-based care.

Results from the COPE trial suggest that the cost savings may have stemmed from the fact that, while patients in the tele-rehabilitation arms were more likely to have a hospitalization than patients receiving enhanced usual care, these hospitalizations were more likely to have been planned in advance for treatment and not to require intensive care unit (ICU) admissions, thereby resulting in significantly lower lengths of stay.

Because our model used a conservative estimate of hospitalization costs, we have reason to suspect that our estimate may represent a lower bound of cost savings generated by this intervention. For example, our hospitalization model did not specifically incorporate ICU costs due to limitations of the ICU data; however, we can assume the higher ICU admissions experienced by the enhanced usual care arm would

| TABLE 4 | Cost analysis of subset of Collaborative Care to Preserve Performance in Cancer trial participants represented in the Rochester Epidemiology Project data |
| --- | --- | --- | --- | --- |
| Mean (SD) costs per arm (USD) | Arm A | Arm B | Arm C | *P-Value* |
| Total | 18 838 (16 620) | 14 130 (17 918) | 16 351 (20 749) | .079 |
| Inpatient hospitalization | 7841 (16 715) | 1189 (3656) | 2463 (10 100) | .048 |
| Outpatient | 4212 (6569) | 3782 (6116) | 6473 (12 806) | .637 |
| Emergency department | 324 (994) | 82 (311) | 125 (592) | .638 |
| Clinic | 6461 (6615) | 9076 (14 807) | 7290 (10 386) | .284 |

*P-values calculated using the Kruskal-Wallis test.
have contributed significantly to their overall costs. Patients in the tele-rehabilitation arm (arm B) were also more likely to be discharged home rather than to a skilled nursing facility, which we can also assume would result in additional cost savings. Our secondary analysis of the subset of patients included in the REP data suggests further cost savings from the tele-rehabilitation intervention when total health-care utilization costs are taken into consideration, although we acknowledge that these data are limited given the small sample size of patients included in the REP subset and the statistically nonsignificant results for cost categories other than inpatient hospitalizations. However, a strength of the REP data is its comprehensive charge capture across all payers. Additional research that is able to incorporate these data for an entire study sample would be useful in improving model precision, as well as the generalizability of the results.

Another limitation of our study is that the time horizon of the decision model was limited to the intervention period (6 months) for each participant. As a result, we were not able to capture any longer term impact on patient quality of life, health-care utilization, or costs. However, this limitation is mitigated somewhat given the life expectancy of individuals in this patient population and the fact that the intervention aimed to improve the quality of life, rather than to extend survival.

5 | CONCLUSION

The delivery of a CCM-based, centralized tele-rehabilitation intervention to patients with advanced stage cancer and functional limitations appears to be highly cost-effective. Clinicians and care teams working with this vulnerable population should consider incorporating such interventions into their patient care plans.

ORCID

Colleen F. Longacre https://orcid.org/0000-0002-5484-5004
Andrea L. Cheville https://orcid.org/0000-0001-7668-6115

REFERENCES

1. Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient. 2017;10:295-309.
2. Gordon N, Stemmer SM, Greenberg D, Goldstein DA. Trajectories of injectable cancer drug costs after launch in the United States. J Clin Oncol. 2018;36:319-325.
3. Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370.
4. Ramsey SD, Bansal A, Fedoreenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980-986.
5. National Cancer Institute. 2019. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-pdq. Accessed October 2, 2019.
6. Chan RJ, Gordon LG, Tan CJ, et al. Relationships between financial toxicity and symptom burden in cancer survivors: a systematic review. J Pain Symptom Manage. 2019;57(464-60):e1.
7. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68:153-165.
8. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87:935-943.
9. Singletary J. The costs of cancer care: addressing patient costs. Am Soc Cancer Soc Cancer Act Network. 2017. https://www.fightcancer.org/sites/default/files/Costs%20of%20Cancer%20-%20Financial%20Web.pdf. Accessed September 21, 2019.
10. Reinke T. CMS wants to remodel cancer payment. Care. Manage Care. 2016;25:12-15.
11. Kline RM, Muldoon LD, Schumacher HK, et al. Design challenges of an episode-based payment model in oncology: the centers for medicare & medicaid services oncology care model. J Oncol Pract. 2017;13:e632-e645.
12. Considine J, Berry D, Newnham E, et al. Factors associated with unplanned readmissions within 1 day of acute care discharge: a retrospective cohort study. BMC Health Serv Res. 2018;18:713.
13. Sokoloff C, Daoost P, Paquet J, Chauny JM. Is adequate pain relief time and analgesia associated with emergency department length of stay? A retrospective study. BMJ Open. 2014;4:e004288.
14. Nipp RD, El-Jawahri A, Moran SM, et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017;123:4720-4727.
15. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557-565.
16. Cheville AL, Alberts SR, Rummans TA, et al. Improving adherence to cancer treatment by addressing quality of life in patients with advanced gastrointestinal cancers. J Pain Symptom Manage. 2015;50:321-327.
17. Kroeneke K, Theobald D, Wu J, et al. Effect of telecare management on pain and depression in patients with cancer: a randomized trial. JAMA. 2010;304:163-171.
18. Cheville AL, Moyinihan T, Herrin J, Loprinzi C, Kroeneke K. Effect of collaborative telehabilitation on functional impairment and pain among patients with advanced-stage cancer: a randomized clinical trial. JAMA Oncol. 2019;5:644-652.
19. Choi Yoo SJ, Nyman JA, Cheville AL, Kroeneke K. Cost effectiveness of telecare management for pain and depression in patients with cancer: results from a randomized trial. Gen Hosp Psychiatry. 2014;36:599-606.
20. Meads DM, O’Dwyer JL, Hulme CT, Lopez RR, Bennett MI. Cost-effectiveness of pain management strategies in advanced cancer. Int J Technol Assess Health Care. 2019;35(2):141-149.
21. Malin JL. Wrestling with the high price of cancer care: should we control costs by individuals’ ability to pay or society’s willingness to pay? J Clin Oncol. 2010;28:3212-3214.
22. Cheville AL, Kollasch J, Vandenbarg J, et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage. 2013;45:811-821.
23. Marriott ER, van Hazel G, Gibbs P, Hatswell AJ. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. J Med Econ. 2017;20:193-199.
24. Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. *Med Decis Making*. 2015;35:912-926.

25. Kaiser Family Foundation. 2015. https://www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day

26. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ 3rd. History of the rochester epidemiology project: half a century of medical records linkage in a US population. *Mayo Clin Proc*. 2012;87:1202-1213.

27. St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. *Int J Epidemiol*. 2012;41:1614-1624.

28. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. *Am J Epidemiol*. 2011;173:1059-1068.

29. Visscher SL, Naessens JM, Yawn BP, Reinalda MS, Anderson SS, Borah BJ. Developing a standardized healthcare cost data warehouse. *BMC Health Serv Res*. 2017;17:396.

30. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. *J Am Stat Assoc*. 1952;47:583-621.

31. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. *JAMA*. 2016;316:1093-1103.

32. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. *BMC Health Serv Res*. 2006;6:52.